Clinical and neurobiological predictors of response to ketamine: towards personalized treatment of depression

This open-label trial (n=40) investigated the predictors of response to ketamine in treating moderate to severe depression without psychotic symptoms.

Conducted by the National Institute of Mental Health in the Czech Republic, the study aimed to identify whether ketamine responders differ from non-responders in baseline parameters of anhedonia.

The primary endpoint was the correlation between the change in anhedonia after ketamine administration and the reduction in depressive symptomatology. Secondary objectives included comparing baseline plasmatic levels of specific metabolites, assessing electrophysiological correlates, estimating the influence of demographic and clinical variables, and evaluating cognitive processing speed.

The trial involved adults aged 18 to 65 and employed an open-label design. The study received favorable opinions from the Competent Authority and Ethics Committee. The trial duration was approximately four years, concluding on April 14, 2022.

Topic Depression
Compound Ketamine
Country Czech Republic
Visit trial

Trial Details



Trial Number

Sponsors & Collaborators

National Institute of Mental Health
This company doesn't have a full profile yet, it is linked to a clinical trial.

Data attribution

A large set of the trials in our database are sourced from ClinicalTrials.gov (CTG). We have modified these post to display the information in a more clear format or to correct spelling mistakes. Our database in actively updated and may show a different status (e.g. completed) if we have knowledge of this update (e.g. a published paper on the study) which isn't reflected yet on CTG. If a trial is not sourced from CTG, this is indicated on this page and you can follow the link to the alternative source of information.